{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["VMD-928"],["VMD-928","pembrolizumab"]],"indication":"TrkA overexpression driven solid tumors or lymphoma","name":"NCT03556228","nct_id":"NCT03556228","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03556228. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"VMD-928 tablet monotherapy","label":"VMD-928 monotherapy","type":"EXPERIMENTAL"},{"description":"VMD-928 tablet in combination with fixed dose of pembrolizumab 200 mg once-very-21-day (per cycle)","label":"Combination Therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06","type":"ESTIMATED"},"conditions":["Head and Neck Carcinoma","Adenoid Cystic Carcinoma","Lung Cancer","Non-Small Cell Lung Cancer","Pancreatic Cancer","Mesothelioma","Esophageal Cancer","Any Solid Tumors Progressed After a Prior Immunotherapy","Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma HNSCC","Salivary Gland Carcinomas","Head and Neck Cancers - Salivary Gland","Head and Neck Cancers - Nasopharyngeal","Head and Neck Cancers - Throat","Small Cell Lung Cancer ( SCLC )","Lung Cancer (Locally Advanced or Metastatic)","Head and Neck Cancers - Tonsils","Head and Neck Cancers Hypopharynx","Head and Neck Cancers Larynx","Head and Neck Cancers Lip","Head and Neck Cancers Nasopharynx","Head and Neck Cancers Oral Cavity","Head and Neck Cancers","Head and Neck Cancers Oropharynx","Head and Neck Cancers Trachea"],"enrollment":{"count":242,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"VMD-928 100 mg Tablet","otherNames":["Monotherapy"],"type":"DRUG"},{"name":"VMD-928 Tablet and Pembrolizumab (200 mg)","otherNames":["Combination therapy"],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"VM Oncology, LLC","official_title":"A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number and severity of treatment-emergent Adverse Events (Phase 1)","timeFrame":"First cycle (21 days per cycle)"},{"measure":"To determine the recommended Phase 2 dose for VMD-928 (Phase 1)","timeFrame":"First cycle (21 days per cycle)"},{"measure":"To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)","timeFrame":"First cycle (21 days per cycle)"},{"measure":"Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)","timeFrame":"Up to 18 months"},{"measure":"Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)","timeFrame":"Up to 18 months"}],"references":[],"start_date":{"date":"2018-06-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","url":"https://clinicaltrials.gov/study/NCT03556228"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03556228"}